NCT06920329View on ClinicalTrials.gov

Effects of Peginterferon Consolidation Therapy on Hepatic cccDNA Dynamics in CHB Patients Achieving Clinical Cure.

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 20, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Chronic Hepatitis b
Interventions
DRUG

Peginterferon α-2b based injection

Peginterferon α-2b injection, 180 μg administered subcutaneously in the abdomen or thigh once weekly, with regular follow-up for HBV recurrence. Patients will be followed up every 12 weeks.

Trial Locations (1)

Unknown

Xiamen Hospital of Traditional Chinese Medicine, Xiamen

All Listed Sponsors
lead

Xiamen Hospital of Traditional Chinese Medicine

OTHER

NCT06920329 - Effects of Peginterferon Consolidation Therapy on Hepatic cccDNA Dynamics in CHB Patients Achieving Clinical Cure. | Biotech Hunter | Biotech Hunter